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A b s t r a c t
Introduction: Transapical access (TA) transcatheter aortic valve implantation (TAVI) (TA-TAVI) represents one of the possible 
routes in patients with severe aortic stenosis (AS) who are not suitable for transfemoral access.
Aim: To assess early- and mid-term clinical outcomes after TA-TAVI.
Material and methods: Patients with severe symptomatic AS undergoing TA-TAVI from November 2008 to December 2019 were 
enrolled. Clinical and procedural characteristics as well as clinical outcomes including all-cause mortality during 12-month follow-up 
were assessed.
Results: Sixty-one consecutive patients underwent TA-TAVI for native AS. Patients were elderly with median age of 80.0 (76.0–
84.0) years; 55.7% were males. Median baseline EuroSCORE I and STS scores were 18.2% (11.6–27.7) and 4.8% (3.3–8.2), respec-
tively. The procedural success rate was 96.7%. In-hospital, 30-day and 12-month mortality rates were 9.8%; 18.0% and 24.6%, 
respectively. The main periprocedural and in-hospital complications were bleeding complications (14.8%). The following factors 
were associated with 12-month mortality: previous cerebrovascular event (CVE), glomerular filtration rate (GFR), aortic valve area 
(AVA), right ventricular systolic pressure (RVSP) and serum level of N-terminal prohormone of brain natriuretic peptide (NT-proBNP) 
(RR for CVE 3.17, 95% confidence interval (CI): 1.15–8.76: p = 0.026; RR for AVA per 0.1 cm2 1.28, 95% CI: 1.03–1.55: p = 0.024; 
RR for GFR per 1 ml/min 0.96: 95% CI: 0.94–0.99: p = 0.007; RR for NT-proBNP per 1000 pg/ml 1.07: 95% CI: 1.01–1.17: p = 0.033; 
RR for RVSP per 1 mm Hg 1.07: 95% CI 1.02–1.16: p = 0.011). 
Conclusions: Transapical TAVI in high-risk patients provides good hemodynamic results with acceptable outcomes.
Key words: aortic stenosis, high-risk patients, outcomes, transcatheter aortic valve implantation, transapical.
S u m m a r y
Transapical transcatheter aortic valve implantation in patients who are not suitable for a transfemoral approach gives 
a good hemodynamic result with significant clinical improvement. History of cerebrovascular event, impaired renal function, 
aortic valve area, increased NT-proBNP and right ventricular systolic pressure level may be associated with higher mortality at 
the 12-month follow-up.
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Introduction
Aortic valve stenosis (AS) is the most common valvu-
lar disease, the frequency of which significantly increases 
with age. In patients older than 75 years, the incidence 
of 3.4% for severe AS represents a serious healthcare is-
sue in Europe and in the United States [1–3]. For many 
years, a surgical valve replacement was the only effective 
method for AS treatment. Therefore, high risk surgery 
patients were very often left untreated and scheduled 
for pharmacological treatment [4]. Since the first endo-
vascular implantation in 2002, transcatheter aortic valve 
implantation (TAVI) has become a  valuable method for 
non-operable patients and an alternative to conventional 
surgical replacement [2]. During wider implementation of 
transcatheter heart valves, several approaches for TAVI 
were introduced. The transfemoral approach (TF) is the 
most common access route associated with the most 
favorable clinical outcomes [2, 5]. Patients undergoing 
TAVI constitute a very frail population with multiple co-
morbidities [6]. Computed tomography for access site 
evaluation often reveals diffuse severe atherosclerosis 
with massive calcifications and tortuosity in the iliofem-
oral region, which is a  contraindication for femoral ac-
cess. Transapical access (TA) represents one of the possi-
ble routes in patients who are not suitable for TF access. 
However, due to more aggressive intervention compared 
to the TF route and the need for general anesthesia as 
well as the higher risk profile of patients treated with 
TA, the apical approach is not often used nowadays and 
therefore many questions remain about the safety and 
clinical outcomes [7, 8]. 
Aim
The aim of our study was to assess early- and mid-
term clinical outcomes after TA-TAVI in patients with se-
vere AS.
Material and methods
A  total of 61 consecutive high-risk elderly patients 
with severe symptomatic AS undergoing TA-TAVI from 
November 2008 to December 2019 were enrolled. Pa-
tient screening and selection were performed by a mul-
tidisciplinary Heart Team supported by clinical and im-
aging data. The clinical decision was based on logistic 
EuroSCORE I and the Society of Thoracic Surgeons (STS) 
Score [9]. Clinical assessment also included porcelain aor-
ta, advanced liver cirrhosis, severe neurological impair-
ment and frailty status. All procedures were performed 
by a cardiac surgeon and interventional cardiologist. All 
procedures were performed under general anesthesia 
and using Edwards Sapien, XT and Sapien 3 (Edwards 
Lifesciences, Irvine, USA) and ACURATE neo (Boston Sci-
entific, Marlborough, USA). 
After starting a TAVI program in our center, the num-
ber of all procedures annually was relatively low, start-
ing from 30–40. Moreover, the TA route was a predom-
inant access for TAVI, at least during the first year due 
to factors related to patient characteristics, including 
extremely high risk patients with multilevel atherosclero-
sis. Afterwards, TF access was gaining in frequency and 
we ended up with 120 procedures a year, 95% of which 
were performed via the TF approach. The number of TA 
procedures a year was highest between 2008 and 2014, 
reaching even 16 procedures a year, and since 2015 the 
number has dropped to 3–5 TA-TAVIs a year.  
Baseline characteristics, procedural and outcomes 
data were collected. Endpoints of the study included all-
cause mortality at discharge, 30 days and 12 months. 
Other endpoints were assessed according to the recom-
mendations of the Valve Academic Consortium (VARC) 
[10]. The study protocol was approved by the institution-
al ethical board. 
Statistical analysis
Categorical variables were presented as counts and 
percentages. Continuous variables were expressed as 
mean (standard deviation (SD)) or median (interquartile 
range (IQR)), where applicable. Normality was assessed 
via the Shapiro-Wilk test. Lifetime data were presented 
using the Kaplan-Meier estimator and analyzed using the 
Cox proportional hazards model. Simple models were cre-
ated for all relevant variables (baseline, demographics). 
Due to the small number of observations, no multiple 
regression model was created. Two Kaplan-Meier curves 
were compared using a log-rank test. Hazard ratios (HR) 
with 95% confidence intervals (CI) were presented as 
a result of the Cox regression. Statistical analyses were 
performed in JMP 15.2.0 (SAS Institute Inc., Cary, NC, 
USA, 2020)
Results
Sixty-one consecutive patients underwent TA-TAVI 
for native AS. Patients were elderly with median age of 
80.0 years (76.00–84.0), 55.7% were male and 81.0% 
had symptoms of heart failure in III/IV class according 
to the New York Heart Association (NYHA). All patients 
were considered high risk according to median Logis-
tic EuroSCORE I and STS scores 18.2% (11.6–27.7) and 
4.8% (3.3–8.2), respectively. The median aortic valve area 
(AVA) was 0.70 cm2 (0.60–0.90) and the median value of 
the maximal/mean transaortic gradient was 82.0 mm Hg 
(59.5–93.5)/49.0 (36.0–61.0). Baseline clinical and echo-
cardiographic characteristics are presented in Table I. The 
procedure success rate was 96.7%. All patients under-
went balloon aortic valvuloplasty prior to valve deploy-
ment. All patients received only one prosthesis, so no 
valve-in-valve procedure was necessary. In 1 case a sec-
ond valve was used due to problems with the delivery 
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system. Conversion to open heart surgery was required 
in 2 cases, in 1 patient due to a  severe paravalvular 
leak and in the second one due to a problem with apex 
cannulation. Procedural data and results are presented 
in Table II. All of the complications are presented in Ta-
ble III. The remaining procedures were successful, with 
a  good echocardiographic result. Median maximal and 
mean gradient values were 14.0 mm Hg (10.2–21.0) and 
8.00 mm Hg (5.7–12.0), respectively. We found slightly 
lower median left ventricle ejection fraction at discharge 
than admission, 55.0 % (45.0–64.5) vs. 50.0% (43.5–
60.0), p = 0.007. In most cases, we found at most only 
mild regurgitation of bioprosthesis, 90.2%. Periprocedur-
al stroke occurred in 1 case, as did myocardial infarction. 
Although complications related to apex cannulation did 
not occur, the bleeding complication rate was 14.8%, 
while the need of transfusion of packed red blood cells 
occurred in 39.3%. Major bleeding complications were 
mostly associated with a second vascular access for pig-
tail insertion (n = 3). Two cases were associated with pro-
longed drainage from the index access site. Our registry 
showed that the need for pacemaker (PM) implantation, 
during index hospital stay after TAVI, occurred in 6.6%. 
Similarly, PM implantation was required in 6.6% of pa-
tients before the procedure, while on the waiting list. Six 
(9.8%) patients died during the index hospital stay. Three 
patients died due to bleeding complications related to 
gastrointestinal bleeding and retroperitoneal hematoma. 
In 2 cases septic shock and in one myocardial infarction 
were causes of 3 subsequent deaths. The 30-day mortal-
ity rate was 18.0%, and all-cause mortality at 12 months 
was 24.6% (Figure 1). Further analysis revealed factors 
Table I. Baseline characteristics of patients
Parameter Apical access (n = 61)
Age, median (IQR) [years] 80.0 (76.0; 84.0)
Weight, median (IQR) [kg] 72.5 (60.8; 79.5)
BMI, median (IQR) [kg/m2] 26.20 (24.7; 29.0)
Male, n (%) 34 (55.7)
Diabetes mellitus, n (%) 27 (45.0)
Atrial fibrillation, n (%) 22 (36.7)
Hypertension, n (%) 56 (93.3)
CVE, n (%) 11 (18.0)
COPD, n (%) 12 (20.0)   
PCI, n (%) 14 (33.3)
CABG, n (%) 17 (27.9)
GFR, mean ± SD [ml/min] 54.0 ±21.0
NT pro BNP, median (IQR) [pg/ml] 1336.0 (743.0; 8313.5)
Creatinine, median (IQR) [mmol/l] 90 (76.0; 109.0)
Hemoglobin, mean ± SD [g/dl] 11.2 ±1.8
Logistic EuroSCORE, median (IQR) (%) 18.2 (11.6; 27.7)
EuroSCORE 2, median (IQR) (%) 5.3 (3.0; 9.0)
STS, median (IQR) (%) 4.8 (3.3; 8.2)
Ejection fraction, median (IQR) (%) 55.0 (45.0; 64.5)
AVA, median (IQR) [cm2] 0.70 (0.60; 0.90)
AVPG, median (IQR) [mm Hg] 82.0 (59.5; 93.5)
AVMG, median (IQR) [mm Hg] 49.0 (36.0; 61.0)
RVSP [mm Hg] 42.00 (33.0; 57.0)
Data are presented as number and percentage. AVA – aortic valve area, AVMG 
– aortic valve mean gradient, AVPG – aortic valve peak gradient, BMI – body 
mass index, CABG – coronary artery bypass grafting, COPD – chronic obstructive 
pulmonary disease, CVE – cerebrovascular event – stroke or transient ischemic 
attack, EuroSCORE – European System for Cardiac Operative Risk Evaluation, 
GFR – glomerular filtration ratio, IQR – interquartile range, NT pro-BNP – N ter-
minal pro B type natriuretic peptide, PCI – percutaneous coronary intervention, 
STS – Society of Thoracic Surgeons, RVSP – right ventricular systolic pressure.
Table II. Procedural data
Parameter Rresult
Procedure duration, median (IQR) [min ] 115 (95; 152.5)
Radiation dose [mGy] 392 (228; 631.5)
Contrast agent [ml] 150 (103.75; 200.0)
Valve type, n (%):
Balloon expandable 42 (68.8)
Self-expandable 19 (31.2)
AVPG, median (IQR) [mm Hg] 14.0 (10.2; 21.0)
AVMG, median (IQR) [mm Hg] 8.0 (5.8; 12.00)






AVMG – aortic valve mean gradient, AVPG – aortic valve peak gradient, 
IQR – in-terquartile range, PVL – perivalvular leak.
Table III. Major periprocedural complications. Data 
are presented as number and percentage
Complications n (%)
Valve displacement 0
Second valve, bailout 1 (1.6) 
AVB requiring PM1 4 (6.6)
Cardiogenic shock 4 (6.6) 
Conversion to surgery  2 (3.4) 
Cardiac tamponade 2 (3.6)
VARC 2 bleeding complications 9 (14.8)
Major 8 (88.9)
Minor 1 (11.1)
Acute renal failure 5 (8.2)
Blood transfusion 24 (39.3)
Myocardial infarction 1 (1.6) 
Stroke 1 (1.6) 
PM – pacemaker, 1During in-hospital stay.
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which had a strong association with 12-month mortality. 
These were previous CVE (stroke or transient ischemic at-
tack), glomerular filtration rate (GFR), AVA, right ventric-
ular systolic pressure (RVSP) and serum level of N-termi-
nal prohormone of brain natriuretic peptide (NT-proBNP) 
(RR for CVE 3.17, 95% confidence interval (CI): 1.15–8.76: 
p = 0.026; RR for AVA per 0.1 cm2 1.28, 95% CI: 1.03–
1.55: p = 0.024; RR for GFR per 1 ml/min 0.96: 95% CI: 
0.94–0.99: p = 0.007; RR for NT-proBNP per 1000 pg/ml 
1.07: 95% CI: 1.01–1.17: p = 0.033; RR for RVSP per 1 mm 
Hg 1.07: 95% CI: 1.02–1.16: p = 0.011 (Figure 2). Despite 
no statistical significance (p = 0.07), the NYHA class as-
sessment at 30 days showed great clinical improvement; 
93% of survivors were in class I or II. This beneficial ef-
fect was maintained after 6 months: 97.6% of patients in 
class I or II NYHA, p = 0.028. 
Discussion
Currently, TAVI gives the option for an effective treat-
ment for patients who, according to the Heart Team de-
cision, are not appropriate candidates for surgical aortic 
valve replacement [5]. While the transfemoral approach 
gives the best clinical outcomes, it cannot be used in ev-
eryone, particularly not in patients with severe iliofemo-
ral atherosclerosis. Atherosclerosis is a systemic disease 
that included many vascular territories [11]. Peripheral 
artery disease often coexists with significant carotid 
artery stenosis [12]. In severe form, such as porcelain 
aorta, it makes it impossible to even use minimally in-
vasive surgical techniques [13]. In those cases, TA is the 
second choice for transcatheter heart valve delivery, but 
due to its invasive character, bleeding and other com-
plications remain a relevant concern [14]. After starting 
a TAVI program in our center, the TA route was a predom-
inant access for TAVI, at least during the first year due 
to factors related to patient characteristics, including ex-
tremely high risk patients with multilevel atherosclerosis, 
and according to CT-scan assessment TF access was not 
possible in those cases. Our study confirmed that his-
tory of CVE, baseline impaired renal function as well as 
NT-proBNP, RVSP values and AVA may be associated with 
increased mortality. 
In-hospital, 30-day and 12-month mortality rates 
were 9.8%, 18.0% and 24.6%, respectively. In hospital 
mortality, compared to estimated surgical risk accord-
ing to logistic EuroSCORE I Scale 18.2%, was nearly two 
times lower. In a registry of all-comers with a similar re-
cruitment timeframe, Bagienski et al. observed in-hos-
pital, 30-day, 6-month and 12-month mortality of 6.9%, 
 0 21 42 63 84 105 126 147 168 189 210 231 252 273 294 315 336 357
Time [days]
Total 0 days 30 days 182 days 365 days
At risk 59 51 44 34
Cumulative number  
of events
0 11 14 15
Cumulative events 
percentage (%)
0.00 18.64 23.73 25.42
Event probability (%) 0.00 18.98 24.50 26.72
Figure 1. Kaplan-Meier curve for cumulative proba-
bility of death for entire sample
 0 21 42 63 84 105 126 147 168 189 210 231 252 273 294 315 336 357
Time [days]
 CVE         No CVE
Group: No 0 days 30 days 182 days 365 days
At risk 45 40 36 27
Cumulative number  
of events
0 5 8 8
Cumulative events 
percentage (%)
0.00 11.11 17.78 17.78
Event probability (%) 0.00 11.33 18.72 18.72
Group: yes 0 days 30 days 182 days 365 days
At risk 14 11 8 7
Cumulative number  
of events
0 6 6 7
Cumulative events 
percentage (%)
0.00 42.86 42.86 50.00
Event probability (%) 0.00 42.86 42.86 51.02
Figure 2. Kaplan-Meier curve for cumulative proba-
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10.9%, 15.8% and 17.8%, respectively [15]. The 30-day 
mortality in the study group was 18%. Some studies show 
that it can even exceed 20% [16]. On the other hand, 
in a study by Walter et al., the authors observed lower 
30-day mortality with a  survival rate of 91%, but with 
a similar death rate of 27% at 12 months of follow-up. In 
summary, currently available data showed relatively low-
er 30-day mortality rate at 12.2 % and only 3.8% in the 
PARTNER TA group; 12-month mortality was 32.2% and 
29.0%, respectively [5, 14]. The 12-month all-cause mor-
tality reached 24.6% but in the present study TA was the 
only possible method of invasive treatment in the group 
of patients with many comorbidities. Compared with the 
group of patients who received conservative treatment 
in the PARTNER I trial, 12-month mortality in the present 
study was two times lower (24.6% vs. 50.7%) [5]. 
In our study, bleeding, in the majority of cases 
life-threatening, was the most common complication, 
with a  14.8% frequency, yet complications associated 
with apex cannulation did not occur. These values are not 
greater than those available in other registries [17, 18]. 
Bleeding complication rate may be associated with the 
fact that the need of anticoagulation in patients with atri-
al fibrillation (AF) was 36.7%. TA may also be associated 
with new onset of AF [19]. Larger registries confirmed the 
impact of AF on bleeding complications [20]. Presence of 
AF is not only significant in terms of impact for bleed-
ing complications but is strongly related with further 
mortality. In the FRANCE-2 registry all-cause mortality at 
1 year in patients with pre-existing AF was 25.8% and 
was higher in those without AF [19].
The second most common complication was renal 
failure, with a 8.2% rate, which was probably associat-
ed with surgical trauma and the systemic inflammatory 
response, as a  possible cause of injury [14, 21]. These 
results were similar to those previously described [18, 22, 
23]. Another serious adverse event that may occur during 
TAVI is stroke [5].The frequency of periprocedural stroke 
and myocardial infarction in the study group was at the 
same level, 1.6%. This low value may be associated with 
the technical aspect of the procedure performed via the 
TA approach. The small distance between the sheath in-
serted through the apex and aortic valve makes position-
ing and controlled deployment much easier [2]. This fact 
may also have an impact on further procedure results.
The currently available registries made it possible to 
create a predictor model of unfavorable outcomes after 
TAVI. Factors with a significant influence are chronic ox-
ygen therapy, advanced renal failure, atrial fibrillation, 
poor functional capacity, and decreased baseline cog-
nitive function [24–26]. In our study we found that the 
history of CVE is strongly related to increased mortality. 
This fact may be related to TA’s more invasive character, 
which requires general anesthesia and could also cause 
some rehabilitation problems in the postprocedural peri-
od. Importantly, a history of CVE has been considered as 
a predictor of poor prognosis after cardiac surgery and 
included in the Society of Thoracic Surgeons (STS) risk 
score [24]. On the other hand, previous CVEs were not 
included in the EuroSCORE II risk score model. However, 
neither of these risk scores were designed for patients 
scheduled for TAVI [27].
Elevated RVSP is observed quite frequently in patients 
with AS [28]. Among patients undergoing TAVI, concom-
itant PH on echocardiography is found in 20–75% [29]. 
Also, in patients undergoing surgical aortic valve replace-
ment for AS, baseline PH and its severity are associated 
with mortality, serious complications, and worse late 
survival [30]. Thus, patients with very elevated RVSP are 
often disqualified from surgical valve replacement due to 
concerns about high peri-operative morbidity and mor-
tality or doubts about whether or not valve replacement 
will provide any clinical benefit. Data on the impact of PH 
on outcomes after TAVI are less consistent. In the study 
by Lindman et al. increased RVSP was associated with 
increased mortality, repeat hospitalizations, and strokes 
during the first year after TAVI [31]. Barbash et al. reported 
that the presence of RVSP > 50 mm Hg on echocardiogra-
phy increased the mortality rate immediately after TAVI. In 
addition, patients with sPAP > 50 mm Hg had a prolonged 
hospitalization at the intensive care unit [32]. Also, anoth-
er study confirmed a higher mortality rate at 12 months 
among patients with elevated RVSP [33]. In contrast, in 
the FRANCE-2 registry, the 30-day outcome did not differ 
among 2435 TAVI patients with sPAP < 40, 40–60, and 
≥ 60 mm Hg as assessed by echocardiography [34].
Previous studies have confirmed that elevated levels 
of NT-proBNP may be associated with worse outcomes 
[35, 36]. Koskinas et al. reported that an increased value 
of NT-pro BNP is associated with a higher risk of all-cause 
death and cardiovascular death at 2 years and more fre-
quent VARC-2 complications. On the other hand, Ben-Dor 
et al. did not confirm the significant impact of BNP values 
on further mortality [37]. Moreover, RVSP and NT-proBNP 
are not included in risk scores such as the logistic Euro-
SCORE and STS.
Our study had a  relatively small sample size. Data 
were analyzed retrospectively as a registry from a single 
center. 
Conclusions
Transapical TAVI in patients who are not feasible for 
a transfemoral approach gives a good hemodynamic re-
sult with significant clinical improvement. History of CVE, 
impaired renal function, AVA, increased NT-proBNP and 
RVSP level may be associated with higher mortality at 
the 12 months follow-up.
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